Longevity & AgingStem Cell Therapy Restores Dopamine in Parkinson's Patients in Phase II Trial
A Shanghai biotech called XellSmart has launched a Phase II clinical trial for XS411, a stem cell therapy designed to repair dopamine-producing brain cells lost in Parkinson's disease. Unlike current medications that temporarily boost dopamine levels, XS411 transplants lab-grown dopaminergic neurons directly into movement-control regions of the brain. Phase I results from Beijing Tiantan Hospital showed improved motor function, longer symptom-free periods, and brain imaging suggesting the transplanted cells were actively producing dopamine. No adverse events were reported. The new trial will enroll 30 patients aged 50–75, comparing cell therapy against standard treatment over one year, with some control patients potentially crossing over to receive the therapy later.
